InnovAge Holding earnings release, September 8, 2026

InnovAge Holding Corp. (INNV) · Form 8-K, Item 2.02 · Filed · SEC filing

INNOVAGE ANNOUNCES FINANCIAL RESULTS FOR THE

FOURTH QUARTER AND FISCAL YEAR ENDED JUNE 30, 2026

DENVER, CO., September 8, 2026

- InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to frail, predominantly dual-eligible seniors through the Program of All-inclusive Care for the Elderly (PACE), today announced financial results for its fiscal fourth quarter and full year ended June 30, 2026.

“Fiscal 2026 was an exceptional year for InnovAge and reflects the significant progress we have made strengthening the company,” said Patrick Blair, Chief Executive Officer of InnovAge. “We enter Fiscal 2027 in a strong position, with a durable foundation to serve more seniors and to deliver high-quality care. We remain focused on disciplined execution and creating sustainable long-term value for all of our stakeholders.”

Financial Results

Fiscal Year 2026 Financial Performance

• Total revenues of $989.7 million, increased approximately 15.9% compared to $853.7 million in 2025

• Income Before Income Taxes of $0.3 million, increased by 100.8% compared to a Loss Before Income Taxes of $34.0 million in 2025

• Income Before Income Taxes as a percent of revenue increased 4.0 percentage points compared to a Loss Before Income Tax as a percent of revenue of 4.0% in 2025

• Net loss of $0.7 million decreased 98%, compared to a net loss of $35.3 million in 2025

• Net loss margin of 0.1%, increased 4.1 percentage points compared to a net loss margin of 4.1% in 2025

• Net loss attributable to InnovAge Holding Corp. of $2.5 million, or loss of $0.02 per share, compared to a net loss of $30.3 million, or loss of $0.22 per share in 2025

• Center-level Contribution Margin

Financial statements

Income Statement

Three Months Ended — Financial Results (in thousands)

Three Months Ended – June 30, 2026Three Months Ended – June 30, 2025Year Ended – June 30, 2026Year Ended – June 30, 2025
Total revenues261,951221,417989,707853,699
Income (Loss) Before Income Taxes9,667-4,202266-34,027
Net Income (Loss)9,783-5,009-683-35,343
Net Income (Loss) margin3.7-2.3-0.1-4.1
Net Income (Loss) Attributable to InnovAge Holding Corp.8,287-785-2,537-30,313
Net Income (Loss) per share - basic and diluted0.06-0.01-0.02-0.22
Center-level Contribution Margin(1)62,56241,287227,764153,639
Adjusted EBITDA(1)24,28211,32694,57134,462
Adjusted EBITDA margin(1)9.35.19.64

Income Statement

Based on information as of today, September 8, 2026, InnovAge is issuing the following financial guidance. (in millions)

Low – dollars in millionsHigh – dollars in millions
Census8,6258,850
Total Member Months(1)101,000102,500
Total revenues1,0501,085
Adjusted EBITDA(2)105115

Income Statement

Three Months Ended — (IN THOUSANDS, EXCEPT NUMBER OF SHARES AND PER SHARE DATA)

Three Months Ended – June 30, 2026 – (unaudited)Three Months Ended – June 30, 2025 – (unaudited)Year Ended – June 30, 2026Year Ended – June 30, 2025
RevenuesCapitation revenue261,511221,060988,384852,353
RevenuesOther service revenue4403571,3231,346
RevenuesTotal revenues261,951221,417989,707853,699
ExpensesExternal provider costs115,737108,169449,843431,152
ExpensesCost of care, excluding depreciation and amortization83,65271,961312,100268,908
ExpensesSales and marketing9,9337,10034,36128,217
ExpensesCorporate, general and administrative33,07727,823166,489122,058
ExpensesDepreciation and amortization6,3563,39421,14219,510
ExpensesImpairments and loss on assets held for sale3,0505,1203,15413,615
ExpensesTotal expenses251,805223,567987,089883,460
ExpensesOperating Income (Loss)10,146-2,1502,618-29,761
Other Income (Expense)Interest expense, net-772-893-4,258-4,612
Other Income (Expense)Loss on cost and equity method investments-1,409-1,393
Other Income (Expense)Other income, net2932501,9061,739
Other Income (Expense)Total other expense-479-2,052-2,352-4,266
Other Income (Expense)Income (Loss) Before Income Taxes9,667-4,202266-34,027
Other Income (Expense)Provision for Income Taxes-1168079491,316
Other Income (Expense)Net Income (Loss)9,783-5,009-683-35,343
Other Income (Expense)Less: net income (loss) attributable to noncontrolling interests1,496-4,2241,854-5,030
Other Income (Expense)Net Income (Loss) Attributable to InnovAge Holding Corp.8,287-785-2,537-30,313
Other Income (Expense)Weighted-average number of common shares outstanding - basic135,812,522135,133,574135,698,603135,387,555
Other Income (Expense)Weighted-average number of common shares outstanding - diluted137,157,943135,133,574135,698,603135,387,555
Other Income (Expense)Net loss per share - basic0.06-0.01-0.02-0.22
Other Income (Expense)Net loss per share - diluted0.06-0.01-0.02-0.22

Income Statement

Three Months Ended — Adjusted EBITDA

Three Months Ended – June 30, 2026Three Months Ended – June 30, 2025Year Ended – June 30, 2026Year Ended – June 30, 2025
Net income (loss)9,783-5,009-683-35,343
Interest expense, net7728934,2584,612
Other investment income(a)-146-497-1,422-2,247
Depreciation and amortization6,3563,39421,14219,510
Provision for income tax-1168079491,316
Stock-based compensation1,7341,5507,0487,619
Litigation costs and settlements(b)2,8491,62656,96619,367
M&A diligence, transaction and integration(c)-2221,360
Business optimization(d)2,1953,5403,040
Loss on cost and equity method investments(e)1,3931,393
Asset impairments and loss on assets held for sale(f)3,0504,9763,15413,615
(Gain) loss on sale of assets(g)220-381220
Adjusted EBITDA24,28211,32694,57134,462
Net income (loss) margin3.7-2.3-0.1-4.1
Adjusted EBITDA margin9.35.19.64

Income Statement

Three Months Ended

Three Months Ended – March 31, 2026
Net loss-29,940
Interest expense, net988
Other investment income(a)-294
Depreciation and amortization4,824
Provision for income tax167
Stock-based compensation1,790
Litigation costs and settlements(b)51,859
Business optimization(c)1,101
Adjusted EBITDA30,495
Net loss margin-11.9
Adjusted EBITDA margin12.1

Income Statement

Year Ended June 30, 2026 — Center-Level Contribution Margin (in thousands)

Year Ended June 30, 2026 – PACEYear Ended June 30, 2026 – All other(1)Year Ended June 30, 2026 – TotalsYear Ended June 30, 2025 – PACEYear Ended June 30, 2025 – All other(1)Year Ended June 30, 2025 – Totals
Capitation revenue988,384988,384852,353852,353
Other service revenue1,0662571,3233569901,346
Total revenues989,450257989,707852,709990853,699
External provider costs449,843449,843431,152431,152
Cost of care, excluding depreciation and amortization311,967133312,100268,338570268,908
Center-Level Contribution Margin227,640124227,764153,219420153,639
Sales and marketing34,36128,217
Corporate, general and administrative166,489122,058
Depreciation and amortization21,14219,510

Income Statement

Three Months Ended June 30, 2026 — Center-Level Contribution Margin (in thousands)

Three Months Ended June 30, 2026 – PACEThree Months Ended June 30, 2026 – TotalsThree Months Ended June 30, 2025 – PACEThree Months Ended June 30, 2025 – All other(1)Three Months Ended June 30, 2025 – Totals
Capitation revenue261,511261,511221,060221,060
Other service revenue440440104253357
Total revenues261,951261,951221,164253221,417
External provider costs115,737115,737108,169108,169
Cost of care, excluding depreciation and amortization83,65283,65271,81614571,961
Center-Level Contribution Margin62,56262,56241,17910841,287
Sales and marketing9,9337,100
Corporate, general and administrative33,07727,823
Depreciation and amortization6,3563,394
Impairments and loss on assets held for sale3,0505,120
Operating income (loss)10,146-2,150
Other expense-479-2,052
Income (Loss) Before Income Taxes9,667-4,202
Loss Before Income Taxes as a % of revenue3.7-1.9
Center- Level Contribution Margin as a % of revenue23.918.6

Income Statement

Three Months Ended March 31, 2026 — Center-Level Contribution Margin (in thousands)

Three Months Ended March 31, 2026 – PACEThree Months Ended March 31, 2026 – Totals
Capitation revenue251,502251,502
Other service revenue441441
Total revenues251,943251,943
External provider costs113,247113,247
Cost of care, excluding depreciation and amortization77,67677,676
Center-Level Contribution Margin61,02061,020
Sales and marketing8,744
Corporate, general and administrative76,531
Depreciation and amortization4,824
Operating Loss-29,079
Other expense-694
Loss Before Income Taxes-29,773
Loss Before Income Taxes as a % of revenue-11.8
Center- Level Contribution Margin as a % of revenue24.2

Balance Sheet

(IN THOUSANDS, EXCEPT NUMBER OF SHARES)

June 30, 2026June 30, 2025
Current AssetsCash and cash equivalents97,89164,129
Current AssetsShort-term investments43,43541,775
Current AssetsRestricted cash1011
Current AssetsAccounts receivable42,39036,373
Current AssetsPrepaid expenses and other27,31124,472
Current AssetsIncome tax receivable3,2763,310
Current AssetsAssets held for sale6,038
Current AssetsTotal current assets214,313176,108
Noncurrent AssetsProperty and equipment, net166,086168,044
Noncurrent AssetsOperating lease assets21,41226,901
Noncurrent AssetsDeposits and other10,3189,875
Noncurrent AssetsGoodwill142,046142,046
Noncurrent AssetsOther intangible assets, net3,2183,877
Noncurrent AssetsTotal noncurrent assets343,080350,743
Noncurrent AssetsTotal assets557,393526,851
Current LiabilitiesAccounts payable and accrued expenses115,35876,750
Current LiabilitiesReported and estimated claims56,86458,971
Current LiabilitiesDue to Medicaid and Medicare18,26614,382
Current LiabilitiesCurrent portion of long-term debt2,5362,250
Current LiabilitiesCurrent portion of finance lease obligations6,2755,234
Current LiabilitiesCurrent portion of operating lease obligations4,5924,682
Current LiabilitiesLiabilities held for sale2,538
Current LiabilitiesTotal current liabilities203,891164,807
Noncurrent LiabilitiesDeferred tax liability, net9,0518,761
Noncurrent LiabilitiesFinance lease obligations8,2517,535
Noncurrent LiabilitiesOperating lease obligations19,77523,918
Noncurrent LiabilitiesOther noncurrent liabilities2,1281,458
Noncurrent LiabilitiesLong-term debt, net of debt issuance costs45,52157,464
Noncurrent LiabilitiesTotal liabilities288,617263,943
Commitments and Contingencies (See Note 9)Redeemable Noncontrolling Interest (See Note 4)30,01325,010
Stockholders’ EquityCommon stock, $0.001 par value; 500,000,000 authorized as of each of June 30, 2026 and 2025; 137,483,028 issued and 136,020,049 outstanding as of June 30, 2026 and 136,903,271 issued and 135,440,292 outstanding as of June 30, 2025.137137
Stockholders’ EquityTreasury stock at cost, 1,462,979 and 1,462,979 shares as of June 30, 2026 and June 30, 2025, respectively-7,500-7,500
Stockholders’ EquityAdditional paid-in capital348,724343,378
Stockholders’ EquityRetained deficit-105,758-101,047
Stockholders’ EquityTotal InnovAge Holding Corp.235,603234,968
Stockholders’ EquityNoncontrolling interests3,1602,930
Stockholders’ EquityTotal stockholders’ equity238,763237,898
Stockholders’ EquityTotal liabilities and stockholders’ equity557,393526,851

Cash Flow

Year Ended June 30, — (IN THOUSANDS) (in thousands)

Year Ended June 30, – 2026Year Ended June 30, – 2025
Operating ActivitiesNet loss-683-35,343
Adjustments to reconcile net loss to net cash provided by (used in) operating activities(Gain) loss on disposal of assets-418508
Adjustments to reconcile net loss to net cash provided by (used in) operating activitiesProvision for uncollectible accounts524
Adjustments to reconcile net loss to net cash provided by (used in) operating activitiesDepreciation and amortization21,14219,510
Full release

(1) of $227.8 million, increased 48.3% compared to $153.6 million in 2025

• Center-level Contribution Margin

(1) as a percent of revenue of 23.0%, increased 5.0 percentage points compared to 18.0% in 2025

• Adjusted EBITDA

(1) of $94.6 million, an increase of $60.1 million compared to $34.5 million in 2025

• Adjusted EBITDA

(1) margin of 9.6%, an increase of 5.5 percentage points compared to 4.0% in 2025

• Census of approximately 8,230 participants compared to 7,740 participants in 2025

• Member months of approximately 96,050 compared to 89,130 in 2025

(1)

Center-level Contribution Margin, Center-level Contribution Margin as a percent of revenue, Adjusted EBITDA and Adjusted EBITDA margin are non-GAAP measures. For more details and for a definition and reconciliation of these non-GAAP measures to the most closely comparable GAAP measures for the periods indicated, see “Note Regarding Use of Non-GAAP Financial Measures” and “Reconciliation of GAAP and Non-GAAP Measures.”

Full Fiscal Year 2027 Financial Guidance

Based on information as of today, September 8, 2026, InnovAge is issuing the following financial guidance.

Expected results and estimates may be impacted by factors outside the Company’s control, and actual results may be materially different from this guidance. See “Forward-Looking Statements - Safe Harbor” included herein.

(1)

We define Total Member Months as the total number of participants multiplied by the number of months within the respective reporting period in which each participant was enrolled in our program. Management believes this is a useful metric as it more precisely tracks the number of participants the Company serves throughout the year.

(2)

Adjusted EBITDA is a non-GAAP measure. See “Note Regarding Use of Non-GAAP Financial Measures” and “Reconciliation of GAAP and Non-GAAP Measures” for a definition of historical Adjusted EBITDA and a reconciliation to net income (loss), the most closely comparable GAAP measure. The Company is unable to provide guidance for net income (loss) or a reconciliation of the Company’s Adjusted EBITDA guidance because it cannot provide a meaningful or accurate calculation or estimation of certain reconciling items without unreasonable effort. The Company’s inability to do so is due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliation, including variations in effective tax rate, expenses to be incurred for acquisition activities and other one-time or exceptional items.

Conference Call

The Company will host a conference call this afternoon at 5:00 p.m. Eastern Time. A live audio webcast of the call will be available on the Company’s website, https://investor.innovage.com/. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for a limited time. To access the call by phone, please go to this link ( registration link), for dialing instructions and a unique access pin. We encourage participants to dial into the call fifteen minutes ahead of the scheduled start time.

About InnovAge

InnovAge is a market leader in managing the care of high-cost, frail, and predominantly dual-eligible seniors through the Program of All-inclusive Care for the Elderly (PACE). With a mission of enabling older adults to age independently in their own homes for as long as safely possible, InnovAge’s patient-centered care model is designed to improve the quality of care its participants receive while reducing over-utilization of high-cost care settings. InnovAge believes its PACE healthcare model is one in which all constituencies — participants, their families, providers and government payors — “win.” As of June 30, 2026, InnovAge served approximately 8,230 participants across 20 centers in six states. https://www.innovage.com/.

Investor Contact:

Ryan Kubota rkubota@innovage.com

Media Contact: press@innovage.com

Forward-Looking Statements - Safe Harbor... (truncated)t of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “estimate,” “expect,” “project,” “plan,” “intend,” “believe,” “may,” “will,” “should,” “can have,” “likely” and other words and terms of similar meaning in connection with any discussion of the timing or nature of future operating or financial performance or other events.

Forward-looking statements may be identified by the fact that they do not relate strictly to historical or current facts. Examples of forward-looking statements include, among others, statements we may make regarding quarterly or annual guidance; financial outlook, including future revenues and future earnings; the viability of our growth strategy including our ability or expectations to increase the number of participants we serve, build and/or open de novo centers, or to identify and execute acquisitions, joint ventures and strategic partnerships; the expected impact of government policies and the macroeconomic environment; reimbursement and regulatory developments, including potential reductions in PACE reimbursement rates; our ability to control costs, mitigate the effects of elevated expenses or reduced healthcare budgets, expand our payer capabilities, implement clinical value and operational value initiatives and strengthen enterprise functions; results of periodic inspections, reviews and audits, legal proceedings and government investigations and actions; relationships and discussions with regulatory agencies; market developments; and the effects of any of the foregoing on our future results of operations or financial conditions.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on currently available information and our current beliefs, expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control and may cause our actual results and financial condition to differ materially. Important factors that could cause our actual results and financial condition to differ materially include, among others, the following: (i) the viability of our growth strategy, including our ability to find suitable geographies for new centers and to attract new participant and retain existing participants in new and existing centers and our ability to obtain licenses to open such centers; (ii) our ability to identify, successfully complete and integrate acquisitions, joint ventures another strategic partnerships; (iii) the impact on our business from ongoing macroeconomic, geopolitical and industry-related challenges, including labor shortages, labor competition, high inflation, and supply chain disruptions, as a result of tariffs and trade disputes; (iv) the risk that the cost of providing services under our PACE contracts will exceed our compensation; (v) our increased costs and expenditures and our inability to execute or realize the benefits of our clinical and operational value initiatives; (vi) the dependence of our revenues upon a limited number of government payors which exposes us to the risk of government funding reductions, legislative changes and federal and state budgetary pressures; (vii) reductions in PACE reimbursement rates; (viii) the results of periodic inspections, reviews, audits and investigations under the federal and state government programs, including our ability to sufficiently cure any deficiencies identified; (ix) the adverse impact of legal proceedings, enforcement actions and litigation disputes, which are costly to defend; (x) the risk that our submissions to government payors may contain inaccurate or unsupportable information, including regarding risk adjustment scores of participants, subjecting us to repayment obligations or penalties; and (xi) our ability to adhere to complex and changing government laws and regulations in the healthcare industry.

Forward-looking statements are based only on information currently available to us and speaks only as of the date on which it is made. Except as required by law, we undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. We advise you to not place undue reliance on forward-looking statements and to review our risk factors and other disclosures included in the reports we file or furnish with the Securities and Exchange Commission, including our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.

Note Regarding Use of Non-GAAP Financial Measures

In addition to reporting financial information in accordance with generally accepted accounting principles (“GAAP”), the Company is also reporting Center-level Contribution Margin, Center-level Contribution Margin as a percent of revenue, Adjusted EBITDA and Adjusted EBITDA margin, which are non-GAAP financial measures. These non-GAAP measures are supplemental measures of operating performance monitored by management that are not defined under GAAP and that do not represent, and should not be considered as, an alternative to net income (loss) before income taxes, net income (loss) before income taxes margin, net income (loss) and net income (loss) margin, as applicable, as determined by GAAP. We believe that these non-GAAP measures are appropriate measures of operating performance because the metrics eliminate the impact of certain expenses that, in the case of Adjusted EBITDA, do not relate to our ongoing business performance, allowing us to more effectively evaluate our core operating performance and trends from period to period. Our definitions and calculations of non-GAAP measures may vary and not be comparable to similarly titled measures reported by other companies. We believe that these non-GAAP measures help investors and analysts in comparing our results across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our core operating performance. These non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation from, or as a substitute for, the analysis of other comparable GAAP financial measures.

The Company’s management uses Center-level Contribution Margin as the measure for assessing performance of its operating segments and allocating resources, predominantly in the annual budget and forecasting process. For the purpose of evaluating Center-level Contribution Margin on a center-by-center basis, we do not allocate our sales and marketing expense or corporate, general and administrative expenses across our centers. We define Center-level Contribution Margin as total revenues less external provider costs and cost of care, excluding depreciation and amortization, which includes all medical and pharmacy costs.

We define Adjusted EBITDA as net income (loss) adjusted for interest expense, net, other investment income, depreciation and amortization, and provision (benefit) for income tax as well as addbacks for non-recurring expenses or exceptional items, including charges relating to management equity compensation, litigation costs and settlement, M&A diligence, transaction and integration, business optimization, loss on cost and equity method investments, asset impairments and loss on assets held for sale and gain (loss) on sale of assets. Adjusted EBITDA margin is Adjusted EBITDA expressed as a percentage of our total revenue.

Schedule 1

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · InnovAge Holding earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.